Oncology – Gynecologic
Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.
17 Mar, 2022 | 08:16h | UTCAuthor Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations
Related:
Three-year follow-up of 2-dose versus 3-dose HPV vaccine
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
Systematic Review: Perioperative enhanced recovery programs for women with gynecological cancers.
16 Mar, 2022 | 10:05h | UTCPerioperative enhanced recovery programmes for women with gynaecological cancers – Cochrane Library
See also: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (some guidelines are free)
RCT: In women undergoing cytoreductive surgery for ovarian cancer, the addition of hyperthermic intraperitoneal chemotherapy did not improve progression-free and overall survival.
16 Mar, 2022 | 09:41h | UTCRelated:
M-A: Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer.
RCT: Cytoreductive surgery for relapsed ovarian cancer.
Systematic Review: Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
14 Mar, 2022 | 01:17h | UTCPoly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer – Cochrane Library
Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update.
14 Mar, 2022 | 00:40h | UTCNews Release: ASCO Guideline Recommends Addition of Monoclonal Antibody to Invasive Cervical Cancer Management – ASCO Daily News
Cancer risks other than female breast and ovarian cancers associated with BRCA1 and BRCA2 pathogenic variants.
3 Mar, 2022 | 08:14h | UTCCancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology
Commentary: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge
M-A: Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer.
24 Feb, 2022 | 10:02h | UTCSecondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Meta-Analysis Affirms Survival Benefit of Second Surgery in Ovarian Cancer — Mortality decreased with rising rates of complete, optimal cytoreduction at recurrence – MedPage Today (free registration required)
Related:
RCT: Cytoreductive surgery for relapsed ovarian cancer.
Systematic Review: Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer.
23 Feb, 2022 | 10:05h | UTC
German Guidelines for the diagnosis, therapy and follow-up of cervical cancer – Part 1 with recommendations on epidemiology, screening, diagnostics and therapy.
17 Feb, 2022 | 08:47h | UTC
RCT: Trametinib improves progression-free survival compared to standard of care in patients with recurrent low-grade serous ovarian cancer.
13 Feb, 2022 | 21:30h | UTC
Commentary on Twitter
Trial findings suggest MEK inhibitor, trametinib, represents new standard-of-care option for patients with recurrent low-grade serous carcinoma. https://t.co/69glZZdrZF pic.twitter.com/UHeccCj1Rn
— The Lancet (@TheLancet) February 10, 2022
RCT: Survival with Cemiplimab in recurrent cervical cancer.
11 Feb, 2022 | 08:36h | UTCSurvival with Cemiplimab in Recurrent Cervical Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cemiplimab Prolongs Survival in Recurrent Cervical Cancer – HealthDay
Review: Primary and metastatic peritoneal surface malignancies.
2 Feb, 2022 | 08:33h | UTCPrimary and metastatic peritoneal surface malignancies – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Primary and metastatic peritoneal surface malignancies – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Commentary on Twitter
Treatment modalities for #peritoneal surface malignancies can be combined or used sequentially according to underlying #tumour type, disease extent and patients' condition and preference.https://t.co/cIkVAJRSaj pic.twitter.com/PUP1BtoTxE
— Nature Reviews Disease Primers (@DiseasePrimers) December 21, 2021
RCT: Lenvatinib plus pembrolizumab improve outcomes compared to chemotherapy in patients with advanced endometrial cancer.
21 Jan, 2022 | 09:46h | UTCLenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Commentary on Twitter
In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months and 11.4 months, respectively. https://t.co/lzqFDnhAQn pic.twitter.com/Tm2BJZuh1D
— NEJM (@NEJM) January 19, 2022
O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.
20 Jan, 2022 | 08:59h | UTC
RCT: Paclitaxel and Carboplatin noninferior to Paclitaxel and Ifosfamide in patients with carcinosarcoma of the uterus or ovary.
18 Jan, 2022 | 09:10h | UTCRandomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Review: Endometrial cancer.
13 Dec, 2021 | 08:43h | UTCEndometrial cancer – Nature Reviews Disease Primers (free for a limited period – if the link is paywalled, try this one)
Infographic: Endometrial cancer (free for a limited period – if the link is paywalled, try this one)
RCT: Cytoreductive surgery for relapsed ovarian cancer.
2 Dec, 2021 | 09:51h | UTC
Recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
19 Nov, 2021 | 10:33h | UTC
A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.
4 Nov, 2021 | 09:58h | UTCRelated:
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
Commentary on Twitter
NEW—Cervical cancer rates 87% lower in women offered vaccination against human papillomavirus (#HPV) between ages 12-13 than in previous generations, English study confirms.
First direct evidence of cervical cancer prevention using bivalent vaccine: https://t.co/HdQbGIKxZp pic.twitter.com/PMFermHGOv
— The Lancet (@TheLancet) November 3, 2021
RCT: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.
26 Sep, 2021 | 21:43h | UTCCommentary: KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer – The ASCO Post
Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.
26 Aug, 2021 | 08:32h | UTC
Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.
20 Aug, 2021 | 08:39h | UTC
Commentary on Twitter
For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX
— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021
ASCO Resource-Stratified Guideline: Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer.
8 Aug, 2021 | 23:38h | UTCCommentary: ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer – The ASCO Post
Review: Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer
7 May, 2021 | 08:23h | UTCHyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review – JAMA Oncology (free for a limited period)
RCT: No benefit from immune checkpoint inhibitors in newly diagnosed stage III or IV ovarian cancer
25 Apr, 2021 | 20:57h | UTC